Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 354

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 354
---
     |             – |     |          0.0505 |     |               4,967 |
| May 26, 2023                      |     | Registered Direct Offering*                             |     |   276,697,310 |     |             – |     |             – |     |          0.0097 |     |               2,690 |
| June 14, 2023                     |     | Share sub-division and re-designation                   |     |               |     |               |     | 4,063,321,418 |     |             n/a |     |                 n/a |
| December 21, 2023                 |     | Shares issued to purchase Intangible asset (see note 5) |     |   323,684,800 |     |             – |     |             – |     |          0.0040 |     |               1,279 |
| December 21, 2023                 |     | Registered Offering                                     |     |   485,391,200 |     |             – |     |             – |     |          0.0040 |     |               1,918 |
| At December 31, 2023              |     |                                                         |     | 1,189,577,722 |     |     1,000,001 |     | 4,063,321,418 |     |                 |     |                     |

| 10. | Related party transaction |

The Directors consider
there to be no related party transactions during the periods reported other than Directors Remuneration.

| 11. | Contingent liabilities |

The Company entered into an Arrangement
Agreement with Bioasis on December 13, 2022 as amended on December 18, 2022. Under the agreement the Company agreed to acquire the
entire issued share capital of Bioasis for consideration of, in aggregate, approximately C$7.4
million (c£4.4 million). The agreement was subject to shareholder approval. On January 23, 2023 at the General Meeting to
approve the Arrangement Agreement none of the special resolutions were passed and, accordingly, the acquisition of Bioasis did not
proceed. Under the agreement the Company agreed to reimburse Bioasis US$225,000
for expenses relating to the transaction should the Company’s shareholders not approve the transaction. On March 3, 2023 the
Company advised Bioasis that it